S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10

Fulcrum Therapeutics Stock Forecast, Price & News

+0.37 (+1.52 %)
(As of 10/22/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume245,042 shs
Average Volume1.20 million shs
Market Capitalization$998.18 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive FULC News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Fulcrum Therapeutics logo

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$8.82 million
Book Value
$2.91 per share


Net Income
$-70.82 million
Net Margins




Market Cap
$998.18 million
Next Earnings Date
11/9/2021 (Estimated)
Not Optionable


Overall MarketRank

2.50 out of 5 stars

Medical Sector

113th out of 1,359 stocks

Pharmaceutical Preparations Industry

48th out of 666 stocks

Analyst Opinion: 4.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

Fulcrum Therapeutics (NASDAQ:FULC) Frequently Asked Questions

Is Fulcrum Therapeutics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fulcrum Therapeutics stock.
View analyst ratings for Fulcrum Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Fulcrum Therapeutics?

Wall Street analysts have given Fulcrum Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fulcrum Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Fulcrum Therapeutics' next earnings date?

Fulcrum Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Fulcrum Therapeutics

How were Fulcrum Therapeutics' earnings last quarter?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) posted its earnings results on Tuesday, August, 10th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.05. The company had revenue of $4.38 million for the quarter, compared to analysts' expectations of $2.69 million. Fulcrum Therapeutics had a negative trailing twelve-month return on equity of 66.84% and a negative net margin of 481.07%.
View Fulcrum Therapeutics' earnings history

How has Fulcrum Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Fulcrum Therapeutics' stock was trading at $11.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FULC shares have increased by 123.2% and is now trading at $24.77.
View which stocks have been most impacted by COVID-19

What price target have analysts set for FULC?

6 Wall Street analysts have issued 1 year price objectives for Fulcrum Therapeutics' stock. Their forecasts range from $23.00 to $46.00. On average, they expect Fulcrum Therapeutics' stock price to reach $36.33 in the next twelve months. This suggests a possible upside of 46.7% from the stock's current price.
View analysts' price targets for Fulcrum Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Fulcrum Therapeutics' key executives?

Fulcrum Therapeutics' management team includes the following people:

What other stocks do shareholders of Fulcrum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulcrum Therapeutics investors own include VIVUS (VVUS), (PCSA), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Kaleido Biosciences (KLDO), VBI Vaccines (VBIV), Xeris Pharmaceuticals (XERS), CymaBay Therapeutics (CBAY), Evelo Biosciences (EVLO) and Akero Therapeutics (AKRO).

When did Fulcrum Therapeutics IPO?

(FULC) raised $76 million in an initial public offering on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink served as the underwriters for the IPO.

What is Fulcrum Therapeutics' stock symbol?

Fulcrum Therapeutics trades on the NASDAQ under the ticker symbol "FULC."

Who are Fulcrum Therapeutics' major shareholders?

Fulcrum Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Mass General Brigham Inc (0.04%), Strs Ohio (0.02%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Fulcrum Therapeutics stock include Christopher Morabito, Curtis Gale Oltmans, Diego Cadavid, James A Geraghty, Owen B Wallace, Peter G Thomson, Peter G Thomson and Robert J Gould.
View institutional ownership trends for Fulcrum Therapeutics

Which major investors are buying Fulcrum Therapeutics stock?

FULC stock was purchased by a variety of institutional investors in the last quarter, including Mass General Brigham Inc, Strs Ohio, and Nisa Investment Advisors LLC. Company insiders that have bought Fulcrum Therapeutics stock in the last two years include Christopher Morabito, Curtis Gale Oltmans, James A Geraghty, and Peter G Thomson.
View insider buying and selling activity for Fulcrum Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Fulcrum Therapeutics?

Shares of FULC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fulcrum Therapeutics' stock price today?

One share of FULC stock can currently be purchased for approximately $24.77.

How much money does Fulcrum Therapeutics make?

Fulcrum Therapeutics has a market capitalization of $998.18 million and generates $8.82 million in revenue each year. The company earns $-70.82 million in net income (profit) each year or ($2.79) on an earnings per share basis.

How many employees does Fulcrum Therapeutics have?

Fulcrum Therapeutics employs 73 workers across the globe.

What is Fulcrum Therapeutics' official website?

The official website for Fulcrum Therapeutics is www.fulcrumtx.com.

Where are Fulcrum Therapeutics' headquarters?

Fulcrum Therapeutics is headquartered at 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139.

How can I contact Fulcrum Therapeutics?

Fulcrum Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at (617) 651-8851 or via email at [email protected].

This page was last updated on 10/24/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.